Cooper Companies (COO) Lowered to Hold at Cleveland Research

Cooper Companies (NYSE:COO) was downgraded by analysts at Cleveland Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.

Several other equities research analysts also recently weighed in on the company. Zacks Investment Research downgraded Cooper Companies from a “buy” rating to a “hold” rating in a research report on Monday, January 8th. Oppenheimer set a $250.00 target price on Cooper Companies and gave the stock a “hold” rating in a research report on Friday, December 8th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $265.00 target price (down previously from $275.00) on shares of Cooper Companies in a research report on Friday, December 8th. Raymond James Financial reaffirmed a “buy” rating and issued a $265.00 target price on shares of Cooper Companies in a research report on Monday, December 4th. Finally, KeyCorp reaffirmed a “hold” rating on shares of Cooper Companies in a research report on Friday, October 20th. Eight investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Cooper Companies has an average rating of “Hold” and a consensus target price of $259.70.

Cooper Companies (COO) traded up $3.59 during mid-day trading on Friday, reaching $226.76. The company’s stock had a trading volume of 534,126 shares, compared to its average volume of 479,642. Cooper Companies has a 1 year low of $189.41 and a 1 year high of $256.39. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.26 and a current ratio of 2.41. The stock has a market capitalization of $11,260.00, a P/E ratio of 30.15, a PEG ratio of 1.80 and a beta of 0.57.

Cooper Companies (NYSE:COO) last posted its quarterly earnings results on Thursday, December 7th. The medical device company reported $2.65 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.64 by $0.01. Cooper Companies had a return on equity of 16.02% and a net margin of 17.43%. The firm had revenue of $561.50 million during the quarter, compared to the consensus estimate of $558.86 million. During the same quarter in the previous year, the business earned $2.28 earnings per share. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. equities analysts predict that Cooper Companies will post 11.54 earnings per share for the current fiscal year.

In related news, Director A Thomas Bender sold 9,150 shares of the stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $229.17, for a total value of $2,096,905.50. Following the completion of the transaction, the director now owns 11,205 shares of the company’s stock, valued at $2,567,849.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gary S. Petersmeyer sold 785 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $229.06, for a total value of $179,812.10. The disclosure for this sale can be found here. Insiders sold 54,385 shares of company stock valued at $12,289,463 in the last three months. 1.60% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Sentry Investment Management LLC boosted its holdings in Cooper Companies by 0.7% in the second quarter. Sentry Investment Management LLC now owns 2,801 shares of the medical device company’s stock valued at $671,000 after purchasing an additional 19 shares during the last quarter. National Asset Management Inc. boosted its holdings in Cooper Companies by 7.6% in the second quarter. National Asset Management Inc. now owns 1,363 shares of the medical device company’s stock valued at $327,000 after purchasing an additional 96 shares during the last quarter. Advisory Services Network LLC boosted its holdings in Cooper Companies by 30.6% in the second quarter. Advisory Services Network LLC now owns 457 shares of the medical device company’s stock valued at $109,000 after purchasing an additional 107 shares during the last quarter. CIBC Asset Management Inc boosted its holdings in Cooper Companies by 4.2% in the fourth quarter. CIBC Asset Management Inc now owns 5,313 shares of the medical device company’s stock valued at $1,158,000 after purchasing an additional 212 shares during the last quarter. Finally, Edgestream Partners L.P. boosted its holdings in Cooper Companies by 26.0% in the third quarter. Edgestream Partners L.P. now owns 1,128 shares of the medical device company’s stock valued at $267,000 after purchasing an additional 233 shares during the last quarter. 96.35% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Cooper Companies (COO) Lowered to Hold at Cleveland Research” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/09/cleveland-research-lowers-cooper-companies-coo-to-neutral.html.

Cooper Companies Company Profile

The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.

Analyst Recommendations for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply